Overview

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

Status:
Active, not recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This is a randomized, two-period, cross-over Phase 2 study, comparing PK, and assessing safety and tolerability and efficacy of peripheral and central intravenous administration of melflufen in patients with RRMM. It is an international study, enrolling patients in US and Europe. The study will enroll patients following at least 2 lines of prior therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Oncopeptides AB

Treatments:

Dexamethasone
Melphalan